Axsome Therapeutics Inc (GB:0HKF)

Axsome Therapeutics (0HKF) Income Statement


Axsome Therapeutics Income Statement

Last quarter (Q1 2024), Axsome Therapeutics's total revenue was $75.00M, a decrease of -20.70% from the same quarter last year. In Q1, Axsome Therapeutics's net income was $-68.36M. See Axsome Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 250.34M$ 270.60M$ 50.04M-$ 0.00$ 0.00
Cost of Revenue
$ -24.27M$ 26.07M$ 3.30M---
Gross Profit
$ 275.30M$ 244.53M$ 46.74M---
Operating Expense
$ 471.27M$ 427.44M$ 221.34M$ 124.71M$ 99.09M$ 67.11M
Operating Income
$ -280.62M$ -231.82M$ -174.60M$ -124.71M$ -99.09M$ -67.11M
Net Non Operating Interest Income Expense
$ -2.77M-$ -7.33M$ -5.70M$ -2.57M$ -1.24M
Other Income Expense
$ 2.54M$ 6.45M$ -51.67M$ -74.06M$ -1.25M-
Pretax Income
$ -298.00M$ -238.28M$ -181.94M$ -130.40M$ -102.90M$ -68.35M
Tax Provision
$ -1.62M$ 960.00K----
Earnings From Equity Interest Net Of Tax
Net Income Common Stockholders
$ -296.74M$ -239.24M$ -187.13M$ -130.40M$ -102.90M$ -68.35M
Basic EPS
$ -6.38$ -5.27$ -4.60$ -3.47$ -2.77$ -2.01
Diluted EPS
$ -6.38$ -5.27$ -4.60$ -3.47$ -2.77$ -2.01
Basic Average Shares
$ 185.57M$ 45.43M$ 40.66M$ 37.62M$ 37.21M$ 34.02M
Diluted Average Shares
$ 185.57M$ 45.43M$ 40.66M$ 37.62M$ 37.21M$ 34.02M
Dividend Per Share
Total Operating Income As Reported
Reported Normalized Basic E P S
Reported Normalized Diluted E P S
Rent Expense Supplemental
Total Expenses
$ 447.00M$ 404.59M$ 224.64M$ 124.71M$ 99.09M$ 67.11M
Net Income From Continuing And Discontinued Operation
$ -296.38M$ -239.24M$ -187.13M$ -130.40M$ -102.90M$ -68.35M
Normalized Income
$ -298.98M$ -188.24M--$ -101.65M$ -68.35M
Interest Expense
----$ 2.57M$ 1.24M
$ -285.50M$ -231.82M$ -190.11M$ -135.02M$ -100.33M$ -67.11M
$ -276.16M$ -224.99M$ -183.07M$ -132.79M$ -100.26M$ -67.07M
Currency in USD

Axsome Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis